Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug DiscoveryClinical TrialClinical Development

PUBLISHER: Visiongain | PRODUCT CODE: 2050394

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 2050394

Global Women's Clinical Trials & CROs Market Report 2026-2036

PUBLISHED:
PAGES: 456 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 8164.52
PDF (Team License - Up to 6 Users)
USD 9666.03
PDF (Site License)
USD 11355.25
PDF (Enterprise License - Includes Free Datasets)
USD 14348.90

Add to Cart

Description

Table of Contents

List of Tables

The global women's clinical trials and CROs market is valued at US$9.9bn in 2026 and is forecast to reach US$22.3bn by 2036, at a CAGR of 8.5% over the forecast period.

This growth is driven by rising prevalence of women-predominant conditions, expanding regulatory requirements for sex-specific safety evaluation, and increasing adoption of precision medicine and biomarker-driven approaches across reproductive health, oncology, and hormonal disorder indications.

Access a Free Sample of This Report

Download a sample to explore:

  • Market forecasts and segment breakdowns
  • Competitive and company-level insights
  • Key trends shaping the market
  • Trade, policy, and supply chain analysis

Technological Innovation Driving Market Expansion

The growth of precision medicine in women's health is rapidly expanding the number of biomarker-driven clinical programmes that require highly specialised trial infrastructure. As oncology, immunology, reproductive health, and endocrine research move toward molecularly defined subgroups, women's health trials increasingly rely on genomic assays, hormonal biomarkers, pharmacogenomics, and molecular signatures that differ markedly across female life stages.

Decentralised trial models and digital patient recruitment tools are also reshaping how women's health studies are designed and executed. Electronic health record-driven recruitment, remote monitoring platforms, and hybrid trial models are improving enrolment speed, broadening access to diverse female populations, and reducing geographic barriers to participation. In 2025, Lindus Health launched hybrid women's health trials in oncology and reproductive medicine, leveraging more than 30 million electronic health records to double enrolment speed compared to traditional CRO approaches.

CROs are responding to these demands by expanding integrated biomarker services, genomic data platforms, advanced bioanalytical laboratories, and adaptive trial operational systems, reinforcing specialised CRO support as increasingly essential for sponsors operating in women's health.

Trade, Policy & Supply Chain Dynamics

  • The women's clinical trials and CRO market is increasingly shaped by U.S. trade tariff policies, global regulatory frameworks, and cross-border supply chain dynamics.
  • Clinical trials rely on imported laboratory reagents, specialised medical devices, comparator drugs, and biomanufacturing inputs, creating exposure to tariff-related cost escalation across laboratory workflows, sample handling, and technical equipment.
  • Women's health trials are particularly exposed because pregnancy-safe diagnostic tools, hormone-testing kits, and specialised imaging systems tend to come from more limited supplier bases, making them sensitive to import-related price shocks.
  • U.S.-China tariff friction is disrupting the flow of biospecimens, central laboratory operations, and data-processing hardware, forcing rerouting or duplication of services and creating delays in reproductive health and oncology programmes.
  • Sponsors running multinational studies may shift recruitment and site activation away from tariff-affected regions, increasing reliance on CRO networks in India, Southeast Asia, and Europe.

Commercial Impact

  • Cost and pricing pressure: Rising input costs for specialised diagnostics, reagents, and trial equipment are increasing baseline trial budgets and affecting the number of concurrent programmes sponsors can advance
  • Supply chain shifts: Companies are diversifying suppliers, restructuring manufacturing for diagnostic consumables, and distributing central laboratory functions across multiple countries to reduce tariff exposure
  • Operational complexity: Women's clinical trials already require heightened safety oversight, detailed subgroup analyses, and specialised endpoints, meaning even modest increases in cost or logistical friction can extend development timelines
  • Competitive positioning: Elite CROs with supply chain management expertise, global site coordination capability, and tariff-compliant procurement frameworks are attracting new outsourcing demand as a result

Company Intelligence

The women's clinical trials and CRO market is served by a mix of global CRO leaders, specialist women's health research organisations, and large pharmaceutical sponsors competing across trial execution capability, regulatory expertise, and patient recruitment infrastructure.

Leading companies including IQVIA, ICON, Labcorp, Syneos Health, and Charles River Laboratories are strengthening their positions through investment in biomarker services, decentralised trial platforms, and expanded women's health research capabilities.

Competition is increasingly defined by:

  • Biomarker integration and genomic data platform capability
  • Decentralised and hybrid trial execution for diverse female populations
  • Regulatory expertise in sex-specific safety evaluation and pregnancy monitoring
  • Patient recruitment infrastructure and electronic health record-driven enrolment capability

This report analyses how competitive positioning is evolving across 19 leading companies, identifying where value is being created and how strategies are expected to shift over the forecast period.

Key Questions Answered

  • What is the projected women's clinical trials and CROs market size by 2036?
  • Which segments and regions will drive growth?
  • How will precision medicine, biomarker-driven programmes, and decentralised trial models shape market evolution?
  • What is the impact of U.S. trade tariffs on trial costs and cross-border operations?
  • Who are the leading companies and how will their positions evolve?

Report Scope and Data Coverage

  • Global women's clinical trials and CROs market analysis
  • Revenue forecasts to 2036
  • Segment-level modelling across trial phase, indication, study design, sponsor type, and service type
  • Regional and national market forecasts across five regions and 23 leading national markets
  • Competitive intelligence on 19 leading companies

Includes both quantitative forecasting and qualitative strategic analysis, covering technology, competition, policy, and supply chain dynamics.

Segmentation Framework

By Trial Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Indication

  • Reproductive Health & Fertility
  • Breast Cancer
  • Gynaecological Disorders
  • Menopause Management
  • Hormonal Disorders
  • Others

By Study Design

  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials

By Sponsor Type

  • Pharmaceutical & Biotech Companies
  • Clinical Research Organisations (CROs)
  • Government & Public Health Agencies
  • Academic & Research Institutions
  • Non-profit & Patient Advocacy Organisations

By Service Type

  • Trial Design & Management
  • Patient Recruitment & Retention
  • Regulatory & Compliance
  • Clinical Trials Monitoring & Data Management
  • Others

Geographic Coverage

North America

  • U.S.A.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Denmark
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

Company Intelligence Coverage

This report includes detailed profiles of 19 leading companies active in the global women's clinical trials and CRO market, including:

  • Amgen
  • AstraZeneca
  • Bayer
  • Charles River Laboratories
  • Hoffmann-La Roche Ltd
  • GSK plc
  • ICON Plc
  • IQVIA
  • Johnson & Johnson
  • Labcorp
  • Lilly USA, LLC
  • Medpace
  • Medtronic
  • Merck & Co
  • Novartis AG
  • Pfizer Inc
  • Syneos Health
  • Thermo Fisher Scientific
  • WuXi AppTec

Each profile includes:

  • Business overview
  • Financial and market positioning
  • Product and technology capabilities
  • Strategic outlook

Bespoke Intelligence & Customisation

Visiongain also provides tailored intelligence and advisory services aligned to specific client requirements.

This includes:

  • Custom market segmentation and forecasts
  • Competitive benchmarking and strategy analysis
  • Policy and regulatory impact assessment
  • Supply chain and sourcing intelligence
  • Scenario modelling including tariffs and geopolitical risk

Why This Market Intelligence Matters

  • The women's clinical trials and CRO market is evolving rapidly, driven by regulatory momentum, precision medicine expansion, and growing investment in sex-specific research infrastructure.
  • Organisations that understand these dynamics will be better placed to capture outsourcing opportunities, manage operational risk, and strengthen competitive positioning.
  • Purchase the Women's Clinical Trials & CROs Market Report 2026-2036 to access the complete dataset, forecasts, and competitive analysis.

Access the Full Forecast and Competitive Analysis

Show more
Product Code: PHA1391

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Women's Clinical Trials & CROs Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 The Increasing Prevalence of Gender-Specific Diseases Drives Targeted Clinical Research and Treatment Development
      • 3.3.1.2 Rising Awareness of Women's Health Issues Encourages Participation in Clinical Trials
      • 3.3.1.3 Government Initiatives Promote the Inclusion of Women in Clinical Studies for better Data Accuracy
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 High Costs Associated with Women-specific Clinical Trials Limit Participation from Smaller Organizations.
      • 3.3.2.2 Recruitment Challenges due to a Lack of Awareness or Cultural Barriers among Female Participants.
      • 3.3.2.3 Ethical and Regulatory Challenges Delay Approval Processes for Women-Focused Studies.
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Development of Treatments for Menopause, Infertility, and Hormonal Disorders Creates Significant Market Potential.
      • 3.3.3.2 Collaborations Between CROs and Hospitals Expand Access to Diverse Female Populations.
      • 3.3.3.3 The Rising Prevalence of Breast and Gynecological Cancers Drives Women-Focused Therapeutic Research.
  • 3.4 U.S. Tariffs: What's the Impact on Global Women's Clinical Trials & CROs Market?
    • 3.4.1 Overview
    • 3.4.2 V-Shaped Recovery Scenario
      • 3.4.2.1 Why V-Shaped Recovery?
      • 3.4.2.2 Impact from Tariffs
      • 3.4.2.3 Market Dynamics and Demand Recovery
      • 3.4.2.4 Policy and Funding Support
      • 3.4.2.5 Timeframe for Recovery
    • 3.4.3 U-Shaped Recovery Scenario
      • 3.4.3.1 Why U-Shaped Recovery?
      • 3.4.3.2 Impact from Tariffs
      • 3.4.3.3 Market Dynamics and Demand Recovery
      • 3.4.3.4 Policy and Funding Support
      • 3.4.3.5 Timeframe for Recovery
    • 3.4.4 L Shaped Recovery Scenario
      • 3.4.4.1 Why L-Shaped Recovery?
      • 3.4.4.2 Impact from Tariffs
      • 3.4.4.3 Market Dynamics and Demand Recovery
      • 3.4.4.4 Policy and Funding Support
      • 3.4.4.5 Timeframe for Recovery
    • 3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2026-2030) and Long-term (2026-2036) Planning?
    • 3.4.6 Impact of U.S. and China Trade War on Women's Clinical Trials & CROs Market
    • 3.4.7 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
    • 3.4.8 Global Market Tariff Sensitivity and Margin Pressure Analysis
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyers
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat of Substitutes
    • 3.5.5 Threat of New Entrants
  • 3.6 PEST Analysis

4 Women's Clinical Trials & CROs Market Analysis by Clinical Trial Phase

  • 4.1 Key Findings
  • 4.2 Indication Segment: Market Attractiveness Index
  • 4.3 Women's Clinical Trials & CROs Market Size Estimation and Forecast by Clinical Trial Phase
  • 4.4 Phase I
    • 4.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.4.2 Market Share by Region, 2026 & 2036 (%)
  • 4.5 Phase II
    • 4.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.5.2 Market Share by Region, 2026 & 2036 (%)
  • 4.6 Phase III
    • 4.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.6.2 Market Share by Region, 2026 & 2036 (%)
  • 4.7 Phase IV
    • 4.7.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.7.2 Market Share by Region, 2026 & 2036 (%)

5 Women's Clinical Trials & CROs Market Analysis by Indication

  • 5.1 Key Findings
  • 5.2 Indication Segment: Market Attractiveness Index
  • 5.3 Women's Clinical Trials & CROs Market Size Estimation and Forecast by Indication
  • 5.4 Reproductive Health & Fertility
    • 5.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.4.2 Market Share by Region, 2026 & 2036 (%)
  • 5.5 Breast Cancer
    • 5.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.5.2 Market Share by Region, 2026 & 2036 (%)
  • 5.6 Gynaecological Disorders
    • 5.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.6.2 Market Share by Region, 2026 & 2036 (%)
  • 5.7 Menopause Management
    • 5.7.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.7.2 Market Share by Region, 2026 & 2036 (%)
  • 5.8 Hormonal Disorders
    • 5.8.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.8.2 Market Share by Region, 2026 & 2036 (%)
  • 5.9 Others
    • 5.9.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.9.2 Market Share by Region, 2026 & 2036 (%)

6 Women's Clinical Trials & CROs Market Analysis by Study Design

  • 6.1 Key Findings
  • 6.2 Study Design Segment: Market Attractiveness Index
  • 6.3 Women's Clinical Trials & CROs Market Size Estimation and Forecast by Study Design
  • 6.4 Interventional Trials
    • 6.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 6.4.2 Market Share by Region, 2026 & 2036 (%)
  • 6.5 Observational Trials
    • 6.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 6.5.2 Market Share by Region, 2026 & 2036 (%)
  • 6.6 Expanded Access Trials
    • 6.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 6.6.2 Market Share by Region, 2026 & 2036 (%)

7 Women's Clinical Trials & CROs Market Analysis by Sponsor Type

  • 7.1 Key Findings
  • 7.2 Sponsor Type Segment: Market Attractiveness Index
  • 7.3 Women's Clinical Trials & CROs Market Size Estimation and Forecast by Sponsor Type
  • 7.4 Pharmaceutical & Biotech Companies
    • 7.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.4.2 Market Share by Region, 2026 & 2036 (%)
  • 7.5 Clinical Research Organizations (CROs)
    • 7.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.5.2 Market Share by Region, 2026 & 2036 (%)
  • 7.6 Government & Public Health Agencies
    • 7.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.6.2 Market Share by Region, 2026 & 2036 (%)
  • 7.7 Academic & Research Institutions
    • 7.7.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.7.2 Market Share by Region, 2026 & 2036 (%)
  • 7.8 Non-profit & Patient Advocacy Organizations
    • 7.8.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.8.2 Market Share by Region, 2026 & 2036 (%)

8 Women's Clinical Trials & CROs Market Analysis by Service Type

  • 8.1 Key Findings
  • 8.2 Service Type Segment: Market Attractiveness Index
  • 8.3 Women's Clinical Trials & CROs Market Size Estimation and Forecast by Service Type
  • 8.4 Trial Design & Management
    • 8.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.4.2 Market Share by Region, 2026 & 2036 (%)
  • 8.5 Patient Recruitment & Retention
    • 8.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.5.2 Market Share by Region, 2026 & 2036 (%)
  • 8.6 Regulatory & Compliance
    • 8.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.6.2 Market Share by Region, 2026 & 2036 (%)
  • 8.7 Clinical Trials Monitoring & Data Management
    • 8.7.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.7.2 Market Share by Region, 2026 & 2036 (%)
  • 8.8 Others
    • 8.8.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.8.2 Market Share by Region, 2026 & 2036 (%)

9 Women's Clinical Trials & CROs Market Analysis by Region

  • 9.1 Key Findings
  • 9.2 Regional Market Size Estimation and Forecast

10 North America Women's Clinical Trials & CROs Market Analysis

  • 10.1 Key Findings
  • 10.2 North America Women's Clinical Trials & CROs Market Attractiveness Index
  • 10.3 North America Women's Clinical Trials & CROs Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 10.4 North America Women's Clinical Trials & CROs Market Size Estimation and Forecast by Country
  • 10.5 North America Women's Clinical Trials & CROs Market Size Estimation and Forecast by Trial Phase
  • 10.6 North America Women's Clinical Trials & CROs Market Size Estimation and Forecast by Indication
  • 10.7 North America Women's Clinical Trials & CROs Market Size Estimation and Forecast by Study Design
  • 10.8 North America Women's Clinical Trials & CROs Market Size Estimation and Forecast by Sponsor Type
  • 10.9 North America Women's Clinical Trials & CROs Market Size Estimation and Forecast by Service Type
  • 10.10 U.S. Women's Clinical Trials & CROs Market Analysis
  • 10.11 Canada Women's Clinical Trials & CROs Market Analysis

11 Europe Women's Clinical Trials & CROs Market Analysis

  • 11.1 Key Findings
  • 11.2 Europe Women's Clinical Trials & CROs Market Attractiveness Index
  • 11.3 Europe Women's Clinical Trials & CROs Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 11.4 Europe Women's Clinical Trials & CROs Market Size Estimation and Forecast by Country
  • 11.5 Europe Women's Clinical Trials & CROs Market Size Estimation and Forecast by Trial Phase
  • 11.6 Europe Women's Clinical Trials & CROs Market Size Estimation and Forecast by Indication
  • 11.7 Europe Women's Clinical Trials & CROs Market Size Estimation and Forecast by Study Design
  • 11.8 Europe Women's Clinical Trials & CROs Market Size Estimation and Forecast by Sponsor Type
  • 11.9 Europe Women's Clinical Trials & CROs Market Size Estimation and Forecast by Service Type
  • 11.10 Germany Women's Clinical Trials & CRO Market Analysis
  • 11.11 France Women's Clinical Trials & CRO Market Analysis
  • 11.12 UK Women's Clinical Trials & CRO Market Analysis
  • 11.13 Italy Women's Clinical Trials & CRO Market Analysis
  • 11.14 Spain Women's Clinical Trials & CRO Market Analysis
  • 11.15 Russia Women's Clinical Trials & CRO Market Analysis
  • 11.16 Rest of Europe Women's Clinical Trials & CRO Market Analysis

12 Asia Pacific Women's Clinical Trials & CROs Market Analysis

  • 12.1 Key Findings
  • 12.2 Asia Pacific Women's Clinical Trials & CROs Market Attractiveness Index
  • 12.3 Asia Pacific Women's Clinical Trials & CROs Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 12.4 Asia Pacific Women's Clinical Trials & CROs Market Size Estimation and Forecast by Country
  • 12.5 Asia Pacific Women's Clinical Trials & CROs Market Size Estimation and Forecast by Trial Phase
  • 12.6 Asia Pacific Women's Clinical Trials & CROs Market Size Estimation and Forecast by Indication
  • 12.7 Asia Pacific Women's Clinical Trials & CROs Market Size Estimation and Forecast by Study Design
  • 12.8 Asia Pacific Women's Clinical Trials & CROs Market Size Estimation and Forecast by Sponsor Type
  • 12.9 Asia Pacific Women's Clinical Trials & CROs Market Size Estimation and Forecast by Service Type
  • 12.10 Japan Women's Clinical Trials & CRO Market Analysis
  • 12.11 China Women's Clinical Trials & CRO Market Analysis
  • 12.12 India Women's Clinical Trials & CRO Market Analysis
  • 12.13 Australia Women's Clinical Trials & CRO Market Analysis
  • 12.14 South Korea Women's Clinical Trials & CRO Market Analysis
  • 12.15 Singapore Women's Clinical Trials & CRO Market Analysis
  • 12.16 Rest of Asia Pacific Women's Clinical Trials & CRO Market Analysis

13 Latin America Women's Clinical Trials & CROs Market Analysis

  • 13.1 Key Findings
  • 13.2 Latin America Women's Clinical Trials & CROs Market Attractiveness Index
  • 13.3 Latin America Women's Clinical Trials & CROs Market by Country, 2026, 2030 & 2036 (US$ Million)
  • 13.4 Latin America Women's Clinical Trials & CROs Market Size Estimation and Forecast by Country
  • 13.5 Latin America Women's Clinical Trials & CROs Market Size Estimation and Forecast by Trial Phase
  • 13.6 Latin America Women's Clinical Trials & CROs Market Size Estimation and Forecast by Indication
  • 13.7 Latin America Women's Clinical Trials & CROs Market Size Estimation and Forecast by Study Design
  • 13.8 Latin America Women's Clinical Trials & CROs Market Size Estimation and Forecast by Sponsor Type
  • 13.9 Latin America Women's Clinical Trials & CROs Market Size Estimation and Forecast by Service Type
  • 13.10 Brazil Women's Clinical Trials & CRO Market Analysis
  • 13.11 Mexico Women's Clinical Trials & CRO Market Analysis
  • 13.12 Argentina Women's Clinical Trials & CRO Market Analysis
  • 13.13 Rest of Latin America Women's Clinical Trials & CRO Market Analysis

14 MEA Women's Clinical Trials & CROs Market Analysis

  • 14.1 Key Findings
  • 14.2 MEA Women's Clinical Trials & CROs Market Attractiveness Index
  • 14.3 MEA Women's Clinical Trials & CROs Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 14.4 MEA Women's Clinical Trials & CROs Market Size Estimation and Forecast by Country
  • 14.5 MEA Women's Clinical Trials & CROs Market Size Estimation and Forecast by Trial Phase
  • 14.6 MEA Women's Clinical Trials & CROs Market Size Estimation and Forecast by Indication
  • 14.7 MEA Women's Clinical Trials & CROs Market Size Estimation and Forecast by Study Design
  • 14.8 MEA Women's Clinical Trials & CROs Market Size Estimation and Forecast by Sponsor Type
  • 14.9 MEA Women's Clinical Trials & CROs Market Size Estimation and Forecast by Service Type
  • 14.10 GCC Women's Clinical Trials & CRO Market Analysis
  • 14.11 South Africa Women's Clinical Trials & CRO Market Analysis
  • 14.12 Rest of MEA Women's Clinical Trials & CRO Market Analysis

15 Company Profiles

  • 15.1 Competitive Landscape, 2025
  • 15.2 Strategic Outlook
  • 15.3 Amgen Inc.
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2018-2024
      • 15.3.3.2 R&D, 2018-2024
      • 15.3.3.3 Regional Market Shares, 2024
    • 15.3.4 Product Benchmarking
    • 15.3.5 SWOT Analysis
    • 15.3.6 Strategic Outlook
  • 15.4 AstraZeneca.
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2018-2024
      • 15.4.3.2 R&D, 2018-2024
      • 15.4.3.3 Regional Market Shares, 2024
      • 15.4.3.4 Business Segment Shares, 2024
    • 15.4.4 Product Benchmarking
    • 15.4.5 SWOT Analysis
    • 15.4.6 Strategic Outlook
  • 15.5 Bayer AG.
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2018-2024
      • 15.5.3.2 R&D, 2018-2024
      • 15.5.3.3 Regional Market Shares, 2024
      • 15.5.3.4 Business Segment Shares, 2024
    • 15.5.4 Product Benchmarking
    • 15.5.5 SWOT Analysis
    • 15.5.6 Strategic Outlook
  • 15.6 Charles River Laboratories
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Net Revenue, 2018-2024
      • 15.6.3.2 Regional Market Shares, 2024
      • 15.6.3.3 Business Segment Shares, 2024
    • 15.6.4 Product Benchmarking
    • 15.6.5 SWOT Analysis
    • 15.6.6 Strategic Outlook
  • 15.7 F. Hoffmann-La Roche Ltd
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
      • 15.7.3.1 Net Revenue, 2018-2024
    • 15.7.4 Product Benchmarking
    • 15.7.5 SWOT Analysis
    • 15.7.6 Strategic Outlook
  • 15.8 GSK plc.
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Financial Analysis
      • 15.8.3.1 Net Revenue, 2018-2024
      • 15.8.3.2 R&D, 2018-2024
      • 15.8.3.3 Regional Market Shares, 2024
      • 15.8.3.4 Business Segment Shares, 2024
    • 15.8.4 Product Benchmarking
    • 15.8.5 SWOT Analysis
    • 15.8.6 Strategic Outlook
  • 15.9 ICON Plc.
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Financial Analysis
      • 15.9.3.1 Net Revenue, 2018-2024
      • 15.9.3.2 Regional Market Shares, 2024
    • 15.9.4 Product Benchmarking
    • 15.9.5 SWOT Analysis
    • 15.9.6 Strategic Outlook
  • 15.10 IQVIA
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Financial Analysis
      • 15.10.3.1 Net Revenue, 2018-2024
      • 15.10.3.2 Regional Market Shares, 2024
      • 15.10.3.3 Business Segment Shares, 2024
    • 15.10.4 Product Benchmarking
    • 15.10.5 SWOT Analysis
    • 15.10.6 Strategic Outlook
  • 15.11 Johnson & Johnson
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Financial Analysis
      • 15.11.3.1 Net Revenue, 2018-2024
      • 15.11.3.2 R&D, 2018-2024
      • 15.11.3.3 Regional Market Shares, 2024
      • 15.11.3.4 Business Segment Shares, 2024
    • 15.11.4 Product Benchmarking
    • 15.11.5 SWOT Analysis
    • 15.11.6 Strategic Outlook
  • 15.12 Labcorp.
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Financial Analysis
      • 15.12.3.1 Net Revenue, 2018-2024
      • 15.12.3.2 Business Segment Shares, 2024
    • 15.12.4 Product Benchmarking
    • 15.12.5 SWOT Analysis
    • 15.12.6 Strategic Outlook
  • 15.13 Lilly USA, LLC
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Financial Analysis
      • 15.13.3.1 Net Revenue, 2018-2024
      • 15.13.3.2 R&D, 2018-2024
      • 15.13.3.3 Regional Market Shares, 2024
      • 15.13.3.4 Business Segment Shares, 2024
    • 15.13.4 Product Benchmarking
    • 15.13.5 SWOT Analysis
    • 15.13.6 Strategic Outlook
  • 15.14 Medpace, Inc.
    • 15.14.1 Company Snapshot
    • 15.14.2 Company Overview
    • 15.14.3 Financial Analysis
      • 15.14.3.1 Net Revenue, 2018-2024
      • 15.14.3.2 Business Segment Shares, 2024
    • 15.14.4 Product Benchmarking
    • 15.14.5 SWOT Analysis
    • 15.14.6 Strategic Outlook
  • 15.15 Medtronic
    • 15.15.1 Company Snapshot
    • 15.15.2 Company Overview
    • 15.15.3 Financial Analysis
      • 15.15.3.1 Net Revenue, 2018-2024
      • 15.15.3.2 R&D, 2018-2024
      • 15.15.3.3 Regional Market Shares, 2024
      • 15.15.3.4 Business Segment Shares, 2024
    • 15.15.4 Product Benchmarking
    • 15.15.5 SWOT Analysis
    • 15.15.6 Strategic Outlook
  • 15.16 Merck & Co., Inc.
    • 15.16.1 Company Snapshot
    • 15.16.2 Company Overview
    • 15.16.3 Financial Analysis
      • 15.16.3.1 Net Revenue, 2018-2024
      • 15.16.3.2 R&D, 2018-2024
      • 15.16.3.3 Regional Market Shares, 2024
      • 15.16.3.4 Business Segment Shares, 2024
    • 15.16.4 Product Benchmarking
    • 15.16.5 SWOT Analysis
    • 15.16.6 Strategic Outlook
  • 15.17 Novartis AG
    • 15.17.1 Company Snapshot
    • 15.17.2 Company Overview
    • 15.17.3 Financial Analysis
      • 15.17.3.1 Net Revenue, 2018-2024
      • 15.17.3.2 R&D, 2018-2024
      • 15.17.3.3 Regional Market Shares, 2024
      • 15.17.3.4 Business Segment Shares, 2024
    • 15.17.4 Product Benchmarking
    • 15.17.5 SWOT Analysis
    • 15.17.6 Strategic Outlook
  • 15.18 Pfizer Inc.
    • 15.18.1 Company Snapshot
    • 15.18.2 Company Overview
    • 15.18.3 Financial Analysis
      • 15.18.3.1 Net Revenue, 2018-2024
      • 15.18.3.2 R&D, 2018-2024
      • 15.18.3.3 Regional Market Shares, 2024
      • 15.18.3.4 Business Segment Shares, 2024
    • 15.18.4 Product Benchmarking
    • 15.18.5 SWOT Analysis
    • 15.18.6 Strategic Outlook
  • 15.19 Syneos Health
    • 15.19.1 Company Snapshot
    • 15.19.2 Company Overview
    • 15.19.3 Financial Analysis
      • 15.19.3.1 Net Revenue, 2018-2024
      • 15.19.3.2 Regional Market Shares, 2024
      • 15.19.3.3 Business Segment Shares, 2024
    • 15.19.4 Product Benchmarking
    • 15.19.5 SWOT Analysis
    • 15.19.6 Strategic Outlook
  • 15.20 Thermo Fisher Scientific
    • 15.20.1 Company Snapshot
    • 15.20.2 Company Overview
    • 15.20.3 Financial Analysis
      • 15.20.3.1 Net Revenue, 2018-2024
      • 15.20.3.2 R&D, 2018-2024
      • 15.20.3.3 Regional Market Shares, 2024
      • 15.20.3.4 Business Segment Shares, 2024
    • 15.20.4 Product Benchmarking
    • 15.20.5 SWOT Analysis
    • 15.20.6 Strategic Outlook
  • 15.21 WuXi AppTec
    • 15.21.1 Company Snapshot
    • 15.21.2 Company Overview
    • 15.21.3 Financial Analysis
      • 15.21.3.1 Net Revenue, 2018-2024
      • 15.21.3.2 Regional Market Shares, 2024
      • 15.21.3.3 Business Segment Shares, 2024
    • 15.21.4 Product Benchmarking
    • 15.21.5 SWOT Analysis
    • 15.21.6 Strategic Outlook

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from Visiongain
  • 16.2 Recommendations for Market Players
Show more
Product Code: PHA1391

List of Tables

  • Table 1 Women's Clinical Trials & CROs Market Snapshot, 2026 & 2036 (US$ Million, CAGR %)
  • Table 2 Women's Clinical Trials & CROs Market: International Trade Tariff Impact Recovery Scenarios Snapshot
  • Table 3 Women's Clinical Trials & CROs Market Forecast by Region 2026-2036 (US$ Million, AGR%, CAGR%), Tariff Impact: V- Shaped Recovery Scenario
  • Table 4 Women's Clinical Trials & CROs Market Forecast by Region 2026-2036 (US$ Million, AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
  • Table 5 Women's Clinical Trials & CROs Market Forecast by Region 2026-2036 (US$ Million, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
  • Table 6 Women's Clinical Trials & CROs Market Forecast by Clinical Trial Phase, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 7 Phase I Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 8 Phase II Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 9 Phase III Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 10 Phase IV Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 11 Women's Clinical Trials & CROs Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 12 Reproductive Health & Fertility Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 13 Breast Cancer Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 14 Gynecological Disorders Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 15 Menopause Management Segment Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 16 Hormonal Disorders Segment Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 17 Others Segment Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 18 Women's Clinical Trials & CROs Market Forecast by Study Design, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 19 Interventional Trials Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 20 Observational Trials Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 21 Expanded Access Trials Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 22 Women's Clinical Trials & CROs Market Forecast by Sponsor Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 23 Pharmaceutical & Biotech Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 24 Clinical Research Organizations (CROs) Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 25 Government & Public Health Agencies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 26 Academic & Research Institutions Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 27 Non-profit & Patient Advocacy Organizations Segment Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 28 Women's Clinical Trials & CROs Market Forecast by Service Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 29 Trial Design & Management Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 30 Patient Recruitment & Retention Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 31 Regulatory & Compliance Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 32 Clinical Trials Monitoring & Data Management Segment Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 33 Others Segment Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 34 Women's Clinical Trials & CROs Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 35 North America Women's Clinical Trials & CROs Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 36 North America Women's Clinical Trials & CROs Market Forecast by Trial Phase, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 37 North America Women's Clinical Trials & CROs Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 38 North America Women's Clinical Trials & CROs Market Forecast by Study Design, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 39 North America Women's Clinical Trials & CROs Market Forecast by Sponsor Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 40 North America Women's Clinical Trials & CROs Market Forecast by Service Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 41 U.S. Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 42 Canada Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 43 Europe Women's Clinical Trials & CROs Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 44 Europe Women's Clinical Trials & CROs Market Forecast by Trial Phase, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 45 Europe Women's Clinical Trials & CROs Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 46 Europe Women's Clinical Trials & CROs Market Forecast by Study Design, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 47 Europe Women's Clinical Trials & CROs Market Forecast by Sponsor Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 48 Europe Women's Clinical Trials & CROs Market Forecast by Service Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 49 Germany Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 50 France Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 51 UK Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 52 Italy Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 53 Spain Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 54 Russia Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 55 Rest of Europe Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 56 Asia Pacific Women's Clinical Trials & CROs Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 57 Asia Pacific Women's Clinical Trials & CROs Market Forecast by Trial Phase, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 58 Asia Pacific Women's Clinical Trials & CROs Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 59 Asia Pacific Women's Clinical Trials & CROs Market Forecast by Study Design, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 60 Asia Pacific Women's Clinical Trials & CROs Market Forecast by Sponsor Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 61 Asia Pacific Women's Clinical Trials & CROs Market Forecast by Service Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 62 Japan Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 63 China Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 64 India Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 65 Australia Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 66 South Korea Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 67 Singapore Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 68 Rest of Asia Pacific Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 69 Latin America Women's Clinical Trials & CROs Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 70 Latin America Women's Clinical Trials & CROs Market Forecast by Trial Phase, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 71 Latin America Women's Clinical Trials & CROs Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 72 Latin America Women's Clinical Trials & CROs Market Forecast by Study Design, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 73 Latin America Women's Clinical Trials & CROs Market Forecast by Sponsor Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 74 Latin America Women's Clinical Trials & CROs Market Forecast by Service Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 75 Brazil Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 76 Mexico Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 77 Argentina Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 78 Rest of Latin America Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 79 Middle East & Africa Women's Clinical Trials & CROs Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 80 MEA Women's Clinical Trials & CROs Market Forecast by Trial Phase, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 81 MEA Women's Clinical Trials & CROs Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 82 MEA Women's Clinical Trials & CROs Market Forecast by Study Design, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 83 MEA Women's Clinical Trials & CROs Market Forecast by Sponsor Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 84 MEA Women's Clinical Trials & CROs Market Forecast by Service Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 85 GCC Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 86 South Africa Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 87 Rest of MEA Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 88 Strategic Outlook
  • Table 89 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 90 Amgen Inc.: Product Benchmarking
  • Table 91 Amgen Inc.: SWOT Analysis
  • Table 92 Amgen Inc.: Strategic Outlook
  • Table 93 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 AstraZeneca: Product Benchmarking
  • Table 95 AstraZeneca: SWOT Analysis
  • Table 96 AstraZeneca: Strategic Outlook
  • Table 97 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 98 Bayer AG: Product Benchmarking
  • Table 99 Bayer AG: SWOT Analysis
  • Table 100 Bayer AG: Strategic Outlook
  • Table 101 Charles River Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102 Charles River Laboratories: Product Benchmarking
  • Table 103 Charles River Laboratories: SWOT Analysis
  • Table 104 Charles River Laboratories: Strategic Outlook
  • Table 105 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 106 F. Hoffmann-La Roche Ltd: Product Benchmarking
  • Table 107 Hoffmann-La Roche Ltd: SWOT Analysis
  • Table 108 F. Hoffmann-La Roche Ltd: Strategic Outlook
  • Table 109 GSK plc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 110 GSK plc.: Product Benchmarking
  • Table 111 GSK plc: SWOT Analysis
  • Table 112 GSK plc.: Strategic Outlook
  • Table 113 ICON Plc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 114 ICON Plc.: Product Benchmarking
  • Table 115 ICON plc: SWOT Analysis
  • Table 116 ICON Plc.: Strategic Outlook
  • Table 117 IQVIA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 118 IQVIA: Product Benchmarking
  • Table 119 IQVIA: SWOT Analysis
  • Table 120 IQVIA: Strategic Outlook
  • Table 121 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 122 Johnson & Johnson: Product Benchmarking
  • Table 123 Johnson & Johnson: SWOT Analysis
  • Table 124 Johnson & Johnson: Strategic Outlook
  • Table 125 Labcorp.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 126 Labcorp.: Product Benchmarking
  • Table 127 Labcorp.: SWOT Analysis
  • Table 128 Labcorp.: Strategic Outlook
  • Table 129 Lilly USA, LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 130 Lilly USA, LLC: Product Benchmarking
  • Table 131 Lilly USA, LLC: SWOT Analysis
  • Table 132 Lilly USA, LLC: Strategic Outlook
  • Table 133 Medpace, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 134 Medpace, Inc.: Product Benchmarking
  • Table 135 Medpace, Inc.: SWOT Analysis
  • Table 136 Medpace, Inc.: Strategic Outlook
  • Table 137 Medtronic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 138 Medtronic: Product Benchmarking
  • Table 139 Medtronic: SWOT Analysis
  • Table 140 Medtronic: Strategic Outlook
  • Table 141 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 142 Merck & Co., Inc.: Product Benchmarking
  • Table 143 Merck & Co., Inc.: SWOT Analysis
  • Table 144 Merck & Co., Inc.: Strategic Outlook
  • Table 145 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 146 Novartis AG.: Product Benchmarking
  • Table 147 Novartis AG.: SWOT Analysis
  • Table 148 Novartis AG: Strategic Outlook
  • Table 149 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 150 Pfizer Inc.: Product Benchmarking
  • Table 151 Pfizer Inc.: SWOT Analysis
  • Table 152 Pfizer Inc.: Strategic Outlook
  • Table 153 Syneos Health(R): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 154 Syneos Health(R).: Product Benchmarking
  • Table 155 Syneos Health: SWOT Analysis
  • Table 156 Syneos Health(R): Strategic Outlook
  • Table 157 Thermo Fisher Scientific: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 158 Thermo Fisher Scientific: Product Benchmarking
  • Table 159 Thermo Fisher Scientific: SWOT Analysis
  • Table 160 Thermo Fisher Scientific: Strategic Outlook
  • Table 161 WuXi AppTec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 162 WuXi AppTec: Product Benchmarking
  • Table 163 WuXi AppTec: SWOT Analysis
  • Table 164 WuXi AppTec: Strategic Outlook

List of Figures

  • Figure 1 Women's Clinical Trials & CROs Market Segmentation
  • Figure 2 Women's Clinical Trials & CROs Market by Trial Phase: Market Attractiveness Index
  • Figure 3 Women's Clinical Trials & CROs Market by Indication: Market Attractiveness Index
  • Figure 4 Women's Clinical Trials & CROs Market by Study Design: Market Attractiveness Index
  • Figure 5 Women's Clinical Trials & CROs Market by Sponsor Type: Market Attractiveness Index
  • Figure 6 Women's Clinical Trials & CROs Market by Service Type: Market Attractiveness Index
  • Figure 7 Women's Clinical Trials & CROs Market Attractiveness Index by Region
  • Figure 8 Women's Clinical Trials & CROs Market: Market Dynamics
  • Figure 9 Women's Clinical Trials & CROs Market: Impact Analysis
  • Figure 10 Women's Clinical Trials & CROs Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
  • Figure 11 Women's Clinical Trials & CROs Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
  • Figure 12 Women's Clinical Trials & CROs Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
  • Figure 13 Short Term & Long Term Planning
  • Figure 14 Impact of U.S. and China Trade War
  • Figure 15 Most Impacted Countries
  • Figure 16 Global Market Tariff Sensitivity and Margin Pressure Analysis
  • Figure 17 Women's Clinical Trials & CROs Market: Porter's Five Forces Analysis
  • Figure 18 Women's Clinical Trials & CROs Market: PEST Analysis
  • Figure 19 Women's Clinical Trials & CROs Market by Clinical Trial Phase: Market Attractiveness Index
  • Figure 20 Women's Clinical Trials & CROs Market Forecast by Clinical Trial Phase, 2026-2036 (US$ Million, AGR %)
  • Figure 21 Women's Clinical Trials & CROs Market Share Forecast by Clinical Trial Phase, 2026, 2031, 2036 (%)
  • Figure 22 Phase I Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 23 Phase I Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 24 Phase II Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 25 Phase II Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 26 Phase III Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 27 Phase III Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 28 Phase IV Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 29 Phase IV Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 30 Women's Clinical Trials & CROs Market by Indication: Market Attractiveness Index
  • Figure 31 Women's Clinical Trials & CROs Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
  • Figure 32 Women's Clinical Trials & CROs Market Share Forecast by Indication, 2026, 2031, 2036 (%)
  • Figure 33 Reproductive Health & Fertility Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 34 Reproductive Health & Fertility Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 35 Breast Cancer Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 36 Breast Cancer Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 37 Gynecological Disorders Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 38 Gynecological Disorders Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 39 Menopause Management Segment Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 40 Menopause Management Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 41 Hormonal Disorders Segment Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 42 Hormonal Disorders Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 43 Others Segment Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 44 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 45 Women's Clinical Trials & CROs Market by Study Design: Market Attractiveness Index
  • Figure 46 Women's Clinical Trials & CROs Market Forecast by Study Design, 2026-2036 (US$ Million, AGR %)
  • Figure 47 Women's Clinical Trials & CROs Market Share Forecast by Study Design, 2026, 2031, 2036 (%)
  • Figure 48 Interventional Trials Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 49 Interventional Trials Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 50 Observational Trials Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 51 Observational Trials Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 52 Expanded Access Trials Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 53 Expanded Access Trials Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 54 Women's Clinical Trials & CROs Market by Sponsor Type: Market Attractiveness Index
  • Figure 55 Women's Clinical Trials & CROs Market Forecast by Sponsor Type, 2026-2036 (US$ Million, AGR %)
  • Figure 56 Women's Clinical Trials & CROs Market Share Forecast by Sponsor Type, 2026, 2031, 2036 (%)
  • Figure 57 Pharmaceutical & Biotech Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 58 Pharmaceutical & Biotech Companies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 59 Clinical Research Organizations (CROs) Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 60 Clinical Research Organizations (CROs) Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 61 Government & Public Health Agencies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 62 Government & Public Health Agencies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 63 Academic & Research Institutions Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 64 Academic Institutions Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 65 Non-profit & Patient Advocacy Organizations Segment Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 66 Non-profit & Patient Advocacy Organizations Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 67 Women's Clinical Trials & CROs Market by Service Type: Market Attractiveness Index
  • Figure 68 Women's Clinical Trials & CROs Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 69 Women's Clinical Trials & CROs Market Share Forecast by Service Type, 2026, 2031, 2036 (%)
  • Figure 70 Trial Design & Management Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 71 Trial Design & Management Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 72 Patient Recruitment & Retention Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 73 Patient Recruitment & Retention Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 74 Regulatory & Compliance Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 75 Regulatory & Compliance Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 76 Clinical Trials Monitoring & Data Management Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 77 Clinical Trials Monitoring & Data Management Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 78 Others Segment Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 79 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 80 Women's Clinical Trials & CROs Market Forecast by Region 2026 and 2036 (Revenue, CAGR%)
  • Figure 81 Women's Clinical Trials & CROs Market Share Forecast by Region 2026, 2031, 2036 (%)
  • Figure 82 Women's Clinical Trials & CROs Market by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 83 North America Women's Clinical Trials & CROs Market Attractiveness Index
  • Figure 84 North America Women's Clinical Trials & CROs Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 85 North America Women's Clinical Trials & CROs Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 86 North America Women's Clinical Trials & CROs Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 87 North America Women's Clinical Trials & CROs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 88 North America Women's Clinical Trials & CROs Market Forecast by Trial Phase, 2026-2036 (US$ Million, AGR %)
  • Figure 89 North America Women's Clinical Trials & CROs Market Share Forecast by Trial Phase, 2026 & 2036 (%)
  • Figure 90 North America Women's Clinical Trials & CROs Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
  • Figure 91 North America Women's Clinical Trials & CROs Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 92 North America Women's Clinical Trials & CROs Market Forecast by Study Design, 2026-2036 (US$ Million, AGR %)
  • Figure 93 North America Women's Clinical Trials & CROs Market Share Forecast by Study Design, 2026 & 2036 (%)
  • Figure 94 North America Women's Clinical Trials & CROs Market Forecast by Sponsor Type, 2026-2036 (US$ Million, AGR %)
  • Figure 95 North America Women's Clinical Trials & CROs Market Share Forecast by Sponsor Type, 2026 & 2036 (%)
  • Figure 96 North America Women's Clinical Trials & CROs Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 97 North America Women's Clinical Trials & CROs Market Share Forecast by Service Type, 2026 & 2036 (%)
  • Figure 98 U.S. Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 99 Canada Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 100 Europe Women's Clinical Trials & CROs Market Attractiveness Index
  • Figure 101 Europe Women's Clinical Trials & CROs Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 102 Europe Women's Clinical Trials & CROs Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 103 Europe Women's Clinical Trials & CROs Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 104 Europe Women's Clinical Trials & CROs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 105 Europe Women's Clinical Trials & CROs Market Forecast by Trial Phase, 2026-2036 (US$ Million, AGR %)
  • Figure 106 Europe Women's Clinical Trials & CROs Market Share Forecast by Trial Phase, 2026 & 2036 (%)
  • Figure 107 Europe Women's Clinical Trials & CROs Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
  • Figure 108 Europe Women's Clinical Trials & CROs Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 109 Europe Women's Clinical Trials & CROs Market Forecast by Study Design, 2026-2036 (US$ Million, AGR %)
  • Figure 110 Europe Women's Clinical Trials & CROs Market Share Forecast by Study Design, 2026 & 2036 (%)
  • Figure 111 Europe Women's Clinical Trials & CROs Market Forecast by Sponsor Type, 2026-2036 (US$ Million, AGR %)
  • Figure 112 Europe Women's Clinical Trials & CROs Market Share Forecast by Sponsor Type, 2026 & 2036 (%)
  • Figure 113 Europe Women's Clinical Trials & CROs Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 114 Europe Women's Clinical Trials & CROs Market Share Forecast by Service Type, 2026 & 2036 (%)
  • Figure 115 Germany Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 116 France Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 117 UK Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 118 Italy Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 119 Spain Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 120 Russia Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 121 Rest of Europe Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 122 Asia Pacific Women's Clinical Trials & CROs Market Attractiveness Index
  • Figure 123 Asia Pacific Women's Clinical Trials & CROs Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 124 Asia Pacific Women's Clinical Trials & CROs Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 125 Asia Pacific Women's Clinical Trials & CROs Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 126 Asia Pacific Women's Clinical Trials & CROs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 127 Asia Pacific Women's Clinical Trials & CROs Market Forecast by Trial Phase, 2026-2036 (US$ Million, AGR %)
  • Figure 128 Asia Pacific Women's Clinical Trials & CROs Market Share Forecast by Trial Phase, 2026 & 2036 (%)
  • Figure 129 Asia Pacific Women's Clinical Trials & CROs Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
  • Figure 130 Asia Pacific Women's Clinical Trials & CROs Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 131 Asia Pacific Women's Clinical Trials & CROs Market Forecast by Study Design, 2026-2036 (US$ Million, AGR %)
  • Figure 132 Asia Pacific Women's Clinical Trials & CROs Market Share Forecast by Study Design, 2026 & 2036 (%)
  • Figure 133 Asia Pacific Women's Clinical Trials & CROs Market Forecast by Sponsor Type, 2026-2036 (US$ Million, AGR %)
  • Figure 134 Asia Pacific Women's Clinical Trials & CROs Market Share Forecast by Sponsor Type, 2026 & 2036 (%)
  • Figure 135 Asia Pacific Women's Clinical Trials & CROs Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 136 Asia Pacific Women's Clinical Trials & CROs Market Share Forecast by Service Type, 2026 & 2036 (%)
  • Figure 137 Japan Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 138 China Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 139 India Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 140 Australia Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 141 South Korea Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 142 Singapore Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 143 Rest of Asia Pacific Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 144 Latin America Women's Clinical Trials & CROs Market Attractiveness Index
  • Figure 145 Latin America Women's Clinical Trials & CROs Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 146 Latin America Women's Clinical Trials & CROs Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 147 Latin America Women's Clinical Trials & CROs Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 148 Latin America Women's Clinical Trials & CROs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 149 Latin America Women's Clinical Trials & CROs Market Forecast by Trial Phase, 2026-2036 (US$ Million, AGR %)
  • Figure 150 Latin America Women's Clinical Trials & CROs Market Share Forecast by Trial Phase, 2026 & 2036 (%)
  • Figure 151 Latin America Women's Clinical Trials & CROs Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
  • Figure 152 Latin America Women's Clinical Trials & CROs Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 153 Latin America Women's Clinical Trials & CROs Market Forecast by Study Design, 2026-2036 (US$ Million, AGR %)
  • Figure 154 Latin America Women's Clinical Trials & CROs Market Share Forecast by Study Design, 2026 & 2036 (%)
  • Figure 155 Latin America Women's Clinical Trials & CROs Market Forecast by Sponsor Type, 2026-2036 (US$ Million, AGR %)
  • Figure 156 Latin America Women's Clinical Trials & CROs Market Share Forecast by Sponsor Type, 2026 & 2036 (%)
  • Figure 157 Latin America Women's Clinical Trials & CROs Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 158 Latin America Women's Clinical Trials & CROs Market Share Forecast by Service Type, 2026 & 2036 (%)
  • Figure 159 Brazil Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 160 Mexico Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 161 Argentina Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 162 Rest of Latin America Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 163 MEA Women's Clinical Trials & CROs Market Attractiveness Index
  • Figure 164 MEA Women's Clinical Trials & CROs Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 165 MEA Women's Clinical Trials & CROs Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 166 MEA Women's Clinical Trials & CROs Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 167 MEA Women's Clinical Trials & CROs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 168 MEA Women's Clinical Trials & CROs Market Forecast by Trial Phase, 2026-2036 (US$ Million, AGR %)
  • Figure 169 MEA Women's Clinical Trials & CROs Market Share Forecast by Trial Phase, 2026 & 2036 (%)
  • Figure 170 MEA Women's Clinical Trials & CROs Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
  • Figure 171 MEA Women's Clinical Trials & CROs Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 172 MEA Women's Clinical Trials & CROs Market Forecast by Study Design, 2026-2036 (US$ Million, AGR %)
  • Figure 173 MEA Women's Clinical Trials & CROs Market Share Forecast by Study Design, 2026 & 2036 (%)
  • Figure 174 MEA Women's Clinical Trials & CROs Market Forecast by Sponsor Type, 2026-2036 (US$ Million, AGR %)
  • Figure 175 MEA Women's Clinical Trials & CROs Market Share Forecast by Sponsor Type, 2026 & 2036 (%)
  • Figure 176 MEA Women's Clinical Trials & CROs Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 177 MEA Women's Clinical Trials & CROs Market Share Forecast by Service Type, 2026 & 2036 (%)
  • Figure 178 GCC Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 179 South Africa Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 180 Rest of MEA Women's Clinical Trials & CROs Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 181 Women's Clinical Trials & CROs Market: Company Share, 2025
  • Figure 182 Amgen Inc.: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 183 Amgen Inc.: R&D, 2018-2024 (US$ Million, AGR%)
  • Figure 184 Amgen Inc. Regional Market Shares, 2024
  • Figure 185 AstraZeneca: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 186 AstraZeneca: R&D, 2018-2024 (US$ Million, AGR%)
  • Figure 187 AstraZeneca Regional Market Shares, 2024
  • Figure 188 AstraZeneca. Business Segment Shares, 2024
  • Figure 189 Bayer AG: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 190 Bayer AG: R&D, 2018-2024 (US$ Million, AGR%)
  • Figure 191 Bayer AG: Regional Market Shares, 2024
  • Figure 192 Bayer AG: Business Segment Shares, 2024
  • Figure 193 Charles River Laboratories: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 194 Charles River Laboratories. Regional Market Shares, 2024
  • Figure 195 Charles River Laboratories. Business Segment Shares, 2024
  • Figure 196 F. Hoffmann-La Roche Ltd: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 197 GSK plc.: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 198 GSK plc.: R&D, 2018-2024 (US$ Million, AGR%)
  • Figure 199 GSK plc. Regional Market Shares, 2024
  • Figure 200 GSK plc.: Business Segment Shares, 2024
  • Figure 201 ICON Plc.: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 202 ICON Plc. Regional Market Shares, 2024
  • Figure 203 IQVIA: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 204 IQVIA. Regional Market Shares, 2024
  • Figure 205 IQVIA: Business Segment Shares, 2024
  • Figure 206 Johnson & Johnson: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 207 Johnson & Johnson: R&D, 2018-2024 (US$ Million, AGR%)
  • Figure 208 Johnson & Johnson. Regional Market Shares, 2024
  • Figure 209 Johnson & Johnson. Business Segment Shares, 2024
  • Figure 210 Labcorp.: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 211 Labcorp. Business Segment Shares, 2024
  • Figure 212 Lilly USA, LLC: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 213 Lilly USA, LLC: R&D, 2018-2024 (US$ Million, AGR%)
  • Figure 214 Lilly USA, LLC. Regional Market Shares, 2024
  • Figure 215 Lilly USA, LLC. Business Segment Shares, 2024
  • Figure 216 Medpace, Inc.: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 217 Medpace, Inc. Business Segment Shares, 2024
  • Figure 218 Medtronic: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 219 Medtronic: R&D, 2018-2024 (US$ Million, AGR%)
  • Figure 220 Medtronic Regional Market Shares, 2024
  • Figure 221 Medtronic Business Segment Shares, 2024
  • Figure 222 Merck & Co., Inc.: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 223 Merck & Co., Inc.: R&D, 2018-2024 (US$ Million, AGR%)
  • Figure 224 Merck & Co., Inc. Regional Market Shares, 2024
  • Figure 225 Merck & Co., Inc. Business Segment Shares, 2024
  • Figure 226 Novartis AG: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 227 Novartis AG: R&D, 2018-2024 (US$ Million, AGR%)
  • Figure 228 Novartis AG. Regional Market Shares, 2024
  • Figure 229 Novartis AG. Business Segment Shares, 2024
  • Figure 230 Pfizer Inc.: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 231 Pfizer Inc.: R&D, 2018-2024 (US$ Million, AGR%)
  • Figure 232 Pfizer Inc. Regional Market Shares, 2024
  • Figure 233 Pfizer Inc. Business Segment Shares, 2024
  • Figure 234 Syneos Health(R): Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 235 Syneos Health(R) Regional Market Shares, 2024
  • Figure 236 Syneos Health(R) Business Segment Shares, 2024
  • Figure 237 Thermo Fisher Scientific: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 238 Thermo Fisher Scientific: R&D, 2018-2024 (US$ Million, AGR%)
  • Figure 239 Thermo Fisher Scientific. Regional Market Shares, 2024
  • Figure 240 Thermo Fisher Scientific. Business Segment Shares, 2024
  • Figure 241 WuXi AppTec: Net Revenue, 2018-2024 (US$ Million, AGR%)
  • Figure 242 WuXi AppTec. Regional Market Shares, 2024
  • Figure 243 WuXi AppTec. Business Segment Shares, 2024
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!